Nordwand Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Nordwand Advisors's BMY Position: Q2 2026 in Review
Nordwand Advisors increased its Bristol-Myers Squibb (BMY) stake by 1.3% in Q2 2026, buying an estimated $5.74K and bringing the position to 8,100 shares worth $467K. The position accounts for 0.07% of the portfolio, ranked #124.
Nordwand Advisors first reported a position in BMY in Q2 2025 and has held it in 5 quarters since. The position peaked at $485K in Q1 2026. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Nordwand Advisors held 8,100 shares of Bristol-Myers Squibb worth $467K as of Q2 2026.
- Nordwand Advisors bought 100 Bristol-Myers Squibb shares in Q2 2026, an estimated $5.74K.
- Bristol-Myers Squibb made up 0.07% of Nordwand Advisors's portfolio in Q2 2026, its #124 holding.
- Nordwand Advisors first reported a position in Bristol-Myers Squibb in Q2 2025 and has held it in 5 quarters since.
- Nordwand Advisors's Bristol-Myers Squibb position peaked at $485K in Q1 2026.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Nordwand Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.